Boston, MA - AiM Medical Robotics, a pioneering company developing cutting-edge robotic technology for neurosurgery, is making significant strides toward validating its innovative surgical robot for deep brain stimulation procedures in Parkinson's patients.

In a series of major announcements, AiM revealed that it has entered into a clinical research agreement with the prestigious Brigham and Women's Hospital (BWH) in Boston. This partnership will allow participating surgeons to utilize AiM's stereotactic neurosurgery robot to accurately deliver deep brain stimulation (DBS) leads with real-time MRI guidance for patients suffering from Parkinson's Disease.

"We are thrilled to be collaborating with Dr. Reese Cosgrove and the exceptional team at Brigham and Women's on this critical study," said Gregory Fischer, CEO of AiM Medical Robotics. "Our robot has the potential to revolutionize deep brain stimulation procedures by counteracting the issue of brain shift, which can lead to suboptimal outcomes."

Brain shift, where the surgical target moves relative to the skull during an operation, has been a longstanding challenge in neurosurgery. According to AiM, a staggering 34% of DBS lead placements require additional surgery or removal due to this issue. The company's robotic system aims to solve this problem through intelligent intraoperative surgical planning and guidance facilitated by real-time soft tissue imaging.

AiM's robot is the culmination of 15 years and $15 million of research funded by the National Institutes of Health (NIH). The company says it is poised to disrupt a $4.3 billion market by addressing the challenges related to the efficient, accurate, and safe intracranial placement of neuromodulation, ablation, and drug delivery devices.

In addition to the clinical study at BWH, AiM also announced the successful completion of a cadaver trial on May 10th, 2024, where the robot precisely delivered DBS leads using real-time MRI guidance. The trial, conducted at the PracticePoint Accelerator Facility with the clinical team from BWH, highlighted the robot's ability to account for brain shift, a significant achievement in the field.

Furthermore, AiM has forged a strategic partnership with Synaptive Medical, a leading provider of advanced imaging and surgical navigation solutions. This collaboration will integrate Synaptive's Modus Nav neuro-navigation software with AiM's robot, creating an optimized workflow for unparalleled precision and efficiency in neurosurgery.

"By combining AiM's MRI-compatible robotic stereotactic frame, Synaptive's advanced navigation software, and intraoperative MRI, we have created an optimized workflow that delivers unparalleled precision and efficiency for deep brain interventions," said Fischer. "This collaboration marks a significant step forward in improving patient outcomes and advancing the field of neurosurgery."

As AiM Medical Robotics continues to make strides in validating its groundbreaking technology, the neurosurgical community eagerly anticipates the potential impact this robotic system could have on improving the lives of patients undergoing complex brain procedures. With partnerships like those with Brigham and Women's Hospital and Synaptive Medical, AiM is well-positioned to lead the way in revolutionizing image-guided stereotactic neurosurgery.